|
2.5 Etiologie - Gènes
|
|
|
|
3.4 Chimioprévention
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
First proposed human test of CRISPR passes initial safety review [Science]
|
|
|
|
|
|
The
proposed clinical trial, in which researchers would use CRISPR to
engineer immune cells to fight cancer, won approval from the Recombinant
DNA Advisory Committee (RAC) at the U.S. National Institutes of Health,
a panel that has traditionally vetted the safety and ethics of gene
therapy trials funded by the U.S. government and others.
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
Nice backs two cancer drugs from Novartis [Pharmafile]
|
|
|
|
|
|
The
independent committee that appraised the drug concluded that ceritinib
was likely to prolong life in people whose disease had progressed after
prior treatment. In addition, Nice recommended Mekinist (trametinib) in
combination with Tafinlar (dabrafenib) to treat a type of skin cancer
that has spread and can’t be surgically removed.
|
|
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10 Politiques
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.8 Communication
|
|
|
|
6.9 Controverses
|
|
|
Clinical Research’s Flaws Highlighted By Stanford’s John Ioannidis [Scope Blog]
|
|
|
|
|
|
In
a new paper with a provocative title, “Why most clinical research is
not useful,” John Ioannidis, MD, DSc, makes the case that despite its
name, much research that aims to improve outcomes in the clinic falls
short, in part, because it isn’t designed to lead “to a favorable change
in decision making… either by itself or when integrated with other
studies and evidence.”
|
|
|
|
|
|